|
|
Volumn 18, Issue 3, 2004, Pages 650-
|
|
Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group [4]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
IMATINIB;
ANTINEOPLASTIC AGENT;
PIPERAZINE DERIVATIVE;
PROTEIN TYROSINE KINASE;
PYRIMIDINE DERIVATIVE;
BONE MARROW SUPPRESSION;
CANCER RESISTANCE;
CELL COUNT;
CHRONIC MYELOID LEUKEMIA;
CONTROLLED STUDY;
CYTOGENETICS;
DISEASE ASSOCIATION;
DRUG RESPONSE;
HIGH RISK POPULATION;
HUMAN;
HUMAN CELL;
LETTER;
MAJOR CLINICAL STUDY;
MEDICAL DECISION MAKING;
MULTIVARIATE ANALYSIS;
NEUTROPENIA;
NEUTROPHIL;
OUTCOMES RESEARCH;
PATIENT CODING;
PHILADELPHIA 1 CHROMOSOME;
PREDICTION;
PRIORITY JOURNAL;
PROGNOSIS;
RISK ASSESSMENT;
SCORING SYSTEM;
SURVIVAL RATE;
SURVIVAL TIME;
THROMBOCYTOPENIA;
TREATMENT FAILURE;
VALIDATION PROCESS;
DRUG ANTAGONISM;
MYELOID LEUKEMIA;
NOTE;
REMISSION;
SALVAGE THERAPY;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
HUMANS;
INTERFERON-ALPHA;
LEUKEMIA, MYELOID, CHRONIC;
LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE;
PIPERAZINES;
PROGNOSIS;
PROTEIN-TYROSINE KINASES;
PYRIMIDINES;
REMISSION INDUCTION;
SALVAGE THERAPY;
SURVIVAL RATE;
TREATMENT OUTCOME;
|
|
EID: 1542503827
PISSN: 08876924
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.leu.2403277 Document Type: Letter |
|
Times cited : (4)
|
|
References (2)
|
